Differences in the Molecular Profile between Primary Breast Carcinomas and Their Cutaneous Metastases.
NGS
breast cancer
immunohistochemistry
metastasis
mutations
pathology
skin
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
23 Feb 2022
23 Feb 2022
Historique:
received:
04
02
2022
revised:
18
02
2022
accepted:
22
02
2022
entrez:
10
3
2022
pubmed:
11
3
2022
medline:
11
3
2022
Statut:
epublish
Résumé
The characterization of molecular alterations of primary breast carcinomas (BC) and their cutaneous metastases (CM) to identify genes involved in the metastatic process have not yet been completely accomplished. To investigate the molecular alterations of BC and their CM, a total of 66 samples (33 BC and 33 CM) from 33 patients were analyzed by immunohistochemical and massive parallel sequencing analyses. In addition, the clinicopathological characteristics of patients and tumors were analyzed. Triple negative (TN) BCs were overrepresented (36.4%) among tumors that developed CM. A change of tumor surrogate molecular type in metastases was found in 15% of patients and 48.5% of the CM presented some additional molecular alteration with respect to the primary tumor, the most frequent were amplification of The TN molecular type has a greater risk of developing skin metastases. There are phenotypic changes and additional molecular alterations in skin metastases compared to the corresponding primary breast tumors in nearly half of the patients. Although these changes do not follow a specific pattern and varied from patient to patient, they could impact on the treatment. More studies with larger patient and sample cohorts are needed.
Sections du résumé
BACKGROUND
BACKGROUND
The characterization of molecular alterations of primary breast carcinomas (BC) and their cutaneous metastases (CM) to identify genes involved in the metastatic process have not yet been completely accomplished.
METHODS
METHODS
To investigate the molecular alterations of BC and their CM, a total of 66 samples (33 BC and 33 CM) from 33 patients were analyzed by immunohistochemical and massive parallel sequencing analyses. In addition, the clinicopathological characteristics of patients and tumors were analyzed.
RESULTS
RESULTS
Triple negative (TN) BCs were overrepresented (36.4%) among tumors that developed CM. A change of tumor surrogate molecular type in metastases was found in 15% of patients and 48.5% of the CM presented some additional molecular alteration with respect to the primary tumor, the most frequent were amplification of
CONCLUSIONS
CONCLUSIONS
The TN molecular type has a greater risk of developing skin metastases. There are phenotypic changes and additional molecular alterations in skin metastases compared to the corresponding primary breast tumors in nearly half of the patients. Although these changes do not follow a specific pattern and varied from patient to patient, they could impact on the treatment. More studies with larger patient and sample cohorts are needed.
Identifiants
pubmed: 35267459
pii: cancers14051151
doi: 10.3390/cancers14051151
pmc: PMC8909188
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Support Oncol. 2004 May-Jun;2(3):271-8
pubmed: 15328826
PLoS Med. 2016 Dec 27;13(12):e1002201
pubmed: 28027327
Adv Anat Pathol. 2020 Jan;27(1):27-35
pubmed: 31045583
Dermatol Ther. 2010 Nov-Dec;23(6):581-9
pubmed: 21054704
Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):444-457
pubmed: 28223433
Cancer Res. 2018 Jun 15;78(12):3112-3121
pubmed: 29615433
Genome Res. 2012 Mar;22(3):568-76
pubmed: 22300766
Diagn Cytopathol. 2011 Dec;39(12):882-7
pubmed: 22081524
J Am Acad Dermatol. 1990 Jan;22(1):19-26
pubmed: 2298962
Cancer Discov. 2022 Feb;12(2):356-371
pubmed: 34544752
N Engl J Med. 2008 Dec 25;359(26):2814-23
pubmed: 19109576
Int J Dermatol. 2014 Feb;53(2):147-58
pubmed: 23557182
Cancer Cell. 2018 Sep 10;34(3):427-438.e6
pubmed: 30205045
Am J Dermatopathol. 2010 May;32(3):222-239
pubmed: 20051816
Exp Mol Pathol. 2016 Jun;100(3):421-5
pubmed: 27095739
Cutis. 2021 Mar;107(3):E29-E36
pubmed: 33956620
South Med J. 2003 Feb;96(2):164-7
pubmed: 12630642
Clin J Oncol Nurs. 2002 Sep-Oct;6(5):255-60
pubmed: 12240484
Cancers (Basel). 2021 Oct 28;13(21):
pubmed: 34771579
J Am Acad Dermatol. 1993 Aug;29(2 Pt 1):228-36
pubmed: 8335743
Acta Cytol. 2017;61(1):47-54
pubmed: 28002821
Am J Dermatopathol. 2012 Jun;34(4):347-93
pubmed: 22617133
Am J Clin Pathol. 2019 Sep 9;152(4):479-485
pubmed: 31172196
Actas Dermosifiliogr. 2008 Mar;99(2):157-9
pubmed: 18346442
Pathol Res Pract. 2020 Apr;216(4):152859
pubmed: 32081510
Indian J Dermatol Venereol Leprol. 2010 Mar-Apr;76(2):125-31
pubmed: 20228540
Acta Dermatovenerol Alp Pannonica Adriat. 2008 Dec;17(4):167-70
pubmed: 19104741
Cancer. 2007 Aug 15;110(4):876-84
pubmed: 17620276
Oncologist. 2017 Sep;22(9):1086-1093
pubmed: 28559413
Breast Cancer Res. 2020 Aug 11;22(1):85
pubmed: 32782013
Oncology. 2011;81(1):55-62
pubmed: 21934337
JAMA. 1990 Feb 23;263(8):1123-6
pubmed: 2405205
Semin Oncol. 2016 Jun;43(3):331-4
pubmed: 27178684
J Clin Invest. 2020 Aug 3;130(8):4252-4265
pubmed: 32657779
An Bras Dermatol. 2015 May-Jun;90(3 Suppl 1):134-7
pubmed: 26312696
Cancer Cell. 2017 Aug 14;32(2):169-184.e7
pubmed: 28810143
Cancer Genomics Proteomics. 2012 Sep-Oct;9(5):311-20
pubmed: 22990110
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Internist (Berl). 2009 Feb;50(2):179-86
pubmed: 19096814
J Am Acad Dermatol. 2009 Mar;60(3):379-87
pubmed: 19056145
Cancer. 1972 May;29(5):1298-307
pubmed: 4336632
Eur J Dermatol. 2017 Dec 1;27(6):609-614
pubmed: 29160213
Clin Cancer Res. 2013 Dec 1;19(23):6380-8
pubmed: 24298068
Cancers (Basel). 2019 Jan 11;11(1):
pubmed: 30641862